Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 244.00p 240.00p 248.00p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -21.0 -55.7 - 78

ReNeuron Group plc Webcast of Preliminary Results

18/06/2019 7:00am

UK Regulatory (RNS & others)


Reneuron (LSE:RENE)
Historical Stock Chart

2 Months : From May 2019 to Jul 2019

Click Here for more Reneuron Charts.

TIDMRENE

RNS Number : 5240C

ReNeuron Group plc

18 June 2019

 
 18 June 2019   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Webcast of Preliminary Results

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will webcast the analyst briefing on the day of its preliminary results, Thursday 11 July 2019.

To listen to the webcast live, please log on to the following web address approximately 5 minutes before 10.00am BST on the day of results:

https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918

A recording of the webcast will later be made available at ReNeuron's website, www.reneuron.com.

The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For more information, please contact Buchanan on reneuron@buchanan.uk.com or 020 7466 5000.

ENDS

ENQUIRIES:

 
ReNeuron                                                                         +44 (0)20 3819 8400 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
 
  Buchanan (UK)                                                                 +44 (0) 20 7466 5000 
Mark Court, Sophie Wills, Tilly Abraham 
 
  Argot Partners (US)                                                                +1 212 600 1902 
  Stephanie Marks, Claudia Styslinger 
 
  Stifel Nicolaus Europe Limited                                                +44 (0) 20 7710 7600 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) 
 
  Nplus1 Singer Advisory LLP                                                    +44 (0) 20 7496 3000 
Aubrey Powell, Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCGGUWCQUPBGAM

(END) Dow Jones Newswires

June 18, 2019 02:00 ET (06:00 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190719 06:05:51